Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telatinib - Bayer/Eddingpharm

Next Previous
Search
Drug Profile

Telatinib - Bayer/Eddingpharm

Alternative Names: BAY-57-9352; EOC-315; Telatinib mesylate

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer ACT Biotech; Cedars-Sinai Medical Center; Eddingpharm
  • Class Antineoplastics; Furans; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Liver cancer; Oesophageal cancer
  • No development reported Colorectal cancer; Solid tumours

Most Recent Events

  • 04 Aug 2021 Phase-II clinical trials in Gastric cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT04798781)
  • 04 Aug 2021 Phase-II clinical trials in Liver cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT04798781)
  • 04 Aug 2021 Phase-II clinical trials in Oesophageal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT04798781)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top